Barlow M, Down L, Mounce LTA, et al. The diagnostic performance of CA-125 for the detection of ovarian cancer in women from different ethnic groups: a cohort study of English primary care data.

The cancer antigen (CA)-125 tumor marker is a glycoprotein expressed on the cell surface of epithelial ovarian cancer cells; levels are elevated in >80% of newly diagnosed ovarian carcinoma ...

This expert discusses recent trends in VTE among ovarian cancer patients—progress to date and work that remains to be done. A leading investigator answers our questions about recent findings.

The researchers analyzed data from more than 200,000 women with ovarian cancer from 2004 through 2020 who’d had a CA-125 blood test.

HealthDay News — Black and American Indian patients are less likely to have elevated cancer antigen (CA)-125 levels at ovarian cancer diagnosis, according to a study published in JAMA Network ...

Mary B. Daly, MD, from the Fox Chase Cancer Center in Philadelphia, and colleagues discuss salpingectomy alone as an option for risk management for women at hereditary risk of ovarian cancer.

Ovarian cancer remains a significant challenge in women's health, with high mortality rates due to late-stage diagnosis. This webinar aims to provide healthcare professionals with an in-depth ...

A previous report suggested the nadir serum CA-125 level within the group of patients with ovarian cancer who achieved normalization of CA-125 accurately defined the risk of relapse. Using similar ...

Purpose In CA-125–based ovarian cancer screening trials, overall specificity and screening sensitivity of ultrasound after an elevated CA-125 exceeded 99.6% and 70%, respectively, thereby yielding a ...

Knowing the symptoms of ovarian cancer – bloating, abdominal pain, eating less and feeling fuller, and trouble with urination or bowel habits – can save a woman's life. Experiencing even one ...

For more information on this research see: Association between Health Insurance Type and Genetic Testing and/or Counseling for Breast and Ovarian Cancer. Journal of Personalized Medicine, 2022,12 ...